Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Atypical multidrug resistance may be associated with catalytically active mutants of human DNA topoisomerase II alpha.

Gene - 11 Jul 2001

Okada Y, Tosaka A, Nimura Y, Kikuchi A, Yoshida S, Suzuki M

Abstract excerpt

In human cells, atypical drug resistance was previously identified with reduced catalytic activity or nuclear localization efficiency of DNA topoisomerase II alpha (TOP2 alpha). We have shown two etoposide resistant hTOP2 alpha mutants, K798L and K798P confer resistance to etoposide. In this work, we showed these mutants are also resistant against doxorubicin and mAMSA in vivo in the yeast strain ISE2, rad52,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amsacrine
Share to Antigens, Neoplasm
Share to DNA, Superhelical

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to DNA Topoisomerases, Type II

Share to Doxorubicin

Share to Drug Resistance, Multiple

Share to Etoposide

Share to Poly-ADP-Ribose Binding Proteins

Source

Identifiers

PMID: 11470519
DOI: 10.1016/s0378-1119(01)00554-6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Atypical multidrug resistance may be associated with catalytically active mutants of human DNA topoisomerase II alpha.PMID 11470519Read ↗

Yeast topoisomerase II mutants resistant to anti-topoisomerase agents: identification and characterization of new yeast topoisomerase II mutants selected for resistance to etoposide.Semantic proximity Read ↗

Drug resistance associated with altered DNA topoisomerase II.Semantic proximity Read ↗

Using yeast to study resistance to topoisomerase II-targeting drugs.Semantic proximity Read ↗

Binding of etoposide to topoisomerase II in the absence of DNA: decreased affinity as a mechanism of drug resistance.Semantic proximity Read ↗

Isolation and characterization of mAMSA-hypersensitive mutants. Cytotoxicity of Top2 covalent complexes containing DNA single strand breaks.Semantic proximity Read ↗

Incidence of mutation and deletion in topoisomerase II alpha mRNA of etoposide and mAMSA-resistant cell lines.Semantic proximity Read ↗

A temperature sensitive topoisomerase II allele confers temperature dependent drug resistance on amsacrine and etoposide: a genetic system for determining the targets of topoisomerase II inhibitors.Semantic proximity Read ↗

Mechanistic studies of amsacrine-resistant derivatives of DNA topoisomerase II. Implications in resistance to multiple antitumor drugs targeting the enzyme.Semantic proximity Read ↗

The top2-5 mutant of yeast topoisomerase II encodes an enzyme resistant to etoposide and amsacrine.Semantic proximity Read ↗

Mutation E522K in human DNA topoisomerase IIbeta confers resistance to methyl N-(4'-(9-acridinylamino)-phenyl)carbamate hydrochloride and methyl N-(4'-(9-acridinylamino)-3-methoxy-phenyl) methane sulfonamide but hypersensitivity to etoposide.Semantic proximity Read ↗

Mechanisms regulating resistance to inhibitors of topoisomerase IISemantic proximity Read ↗

DNA topoisomerase II mutations and resistance to anti-tumor drugs.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.